ROCKVILLE, Md., June 10, 2020 /PRNewswire/ -- REGENXBIO Inc.
(Nasdaq:RGNX), a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy based on its proprietary NAV® Technology
Platform, today announced it will present at the Raymond James
Human Health Innovation Conference on Wednesday, June 17, 2020, at 3:00 p.m. ET. The conference will be held in a
virtual meeting format.
A live webcast of the presentation can be accessed in the
Investors section of REGENXBIO's website
at www.regenxbio.com. An archived replay of the webcast will
be available in the Investors section
of REGENXBIO's website for approximately 30 days
following the presentation.
About REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV® Technology Platform, a
proprietary adeno-associated virus (AAV) gene delivery platform,
consists of exclusive rights to more than 100 novel AAV vectors,
including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its
third-party NAV Technology Platform Licensees are applying the NAV
Technology Platform in the development of a broad pipeline of
candidates in multiple therapeutic areas.
CONTACTS:
Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com
Investors:
Heather Savelle, 212-600-1902
heather@argotpartners.com
Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/regenxbio-to-present-at-the-raymond-james-human-health-innovation-conference-301073344.html
SOURCE REGENXBIO Inc.